Evaluating the Safety of the Intragastric Balloon: Spanish Multicenter Experience in 20,680 Cases and with 12 Different Balloon Models

• Published in: Obesity surgery Vol. 34; no. 8; pp. 2766 - 2777
• Main Authors: Espinet-Coll, Eduard, Del Pozo-García, Andrés J., Turró-Arau, Román, Nebreda-Durán, Javier, Cortés-Rizo, Xavier, Serrano-Jiménez, Andrés, Escartí-Usó, Miguel Ángel, Muñoz-Tornero, María, Carral-Martínez, David, Bernabéu-López, Jaime, Sierra-Bernal, Cristian, Martínez-Ares, David, Espinel-Díez, Jesús, Marra-López Valenciano, Carlos, Sola-Vera, Javier, Sanchís-Artero, Laura, Domínguez-Jiménez, José Luís, Carreño-Macián, Ramiro, Juanmartiñena-Fernández, José Francisco, Fernández-Zulueta, Arnulfo, Consiglieri-Alvarado, Claudia, Galvao-Neto, Manoel
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2024; Springer Nature B.V
• Subjects: Adult; Body mass index; Clinical medicine; Endoscopy; Female; Gastric Balloon; Gastrointestinal surgery; Hospitals; Humans; Hyperinflation; Male; Medicine; Medicine & Public Health; Middle Aged; Mortality; Obesity; Obesity, Morbid - surgery; Original Contributions; Patients; Postoperative Complications - epidemiology; Registries; Retrospective Studies; Spain - epidemiology; Surgery; Transplants & implants; Treatment Outcome; Ulcers; Weight control; Weight Loss; Spain; Obesity; Safety; Adverse events; Complications; Bariatric endoscopy; Intragastric balloon
• ISSN: 0960-8923; 1708-0428; 1708-0428
• DOI: 10.1007/s11695-024-07342-x

Introduction Intragastric balloon (IGB) is a minimally invasive and reversible option for obesity treatment. There is a worldwide growing number of different IGB models. The efficacy and safety profile for each model must be demonstrated. We aim to evaluate IGB safety profile according to the experience of the Spanish Bariatric Endoscopy Group (GETTEMO). Methods A survey of 37 IGBs safety-related questions was sent to all GETTEMO members, to retrospectively collect a multicenter Spanish registry. Incidence, causes, and resolution of both major and minor complications and adverse events (AEs), including legal consequences, differentiated for each balloon model were evaluated. Secondary outcome was weight loss data to confirm efficacy. Results Twenty-one Spanish hospitals experienced in IGBs responded. The overall data encompassed 20,680 IGBs, including 12 different models. Mean %TBWL of 17.66 ± 2.5% was observed. Early removal rate due to intolerance was 3.62%. Mean major complications rate was 0.70% (> 1% in Spatz2, HB, and Spatz3 models), mainly complicated gastric ulcer. Minor AEs rate was 6.37%, mainly esophagitis. Nine cases (0.04%) required surgery. A single case of mortality (0.0048%) occurred. Seven lawsuits (0.0034%) were received, all with favorable resolution. Conclusions In the Spanish experience accumulating 20,680 IGBs and including 12 different balloon models, a low incidence rate of major complications and minor AEs are observed (0.70% and 6.37%, respectively), mostly resolved with medical/endoscopic management. IGB shows good tolerance and efficacy profile. These safety data are within the accepted quality standards. Graphical Abstract